The organizers of INTERPHEX have announced the selection of the event's 2012 advisory board. INTERPHEX 2012 will be held from May 1-3 at the Javits Convention Center in New York City.
The 2012 board members' combined experience represents the spectrum of pharmaceutical and biopharmaceutical manufacturing, and will be instrumental in developing the INTERPHEX 2012 conference programme. They will be joined by Dr Russ Somma, president of SommaTech and a long-time pharmaceutical industry expert, who is consulting with INTERPHEX on restructuring the conference programming. Dr Somma has also joined the volunteer board.
The 2012 advisory board members are Dr Dilip Ashtekar, senior director, quality control, Gilead Sciences; Dr E Morrey Atkinson, chief scientific officer, vice president of research and development, vice president of drug substance manufacturing, Cook Pharmica; E J Brandreth, vice president, quality and regulatory affairs, Althea Technologies; John, Gilroy, P E, senior vice president and principal, Integrated Project Services (IPS); Michelle M Gonzalez, P E, BioPharm Engineering Consultant; Timothy P Howard, C.P.I.P., P E vice president and company officer, Commissioning Agents; M J Kimmel, principal, MJK Solutions; Albert Manigo-Bey, Jr, senior strategic sourcing manager, Watson Pharmaceuticals; Sanjay Patel, senior director, global materials management, Shire Pharmaceuticals; Richard Poska, R.Ph., director, regulatory affairs, Abbott Pharmaceutical Products Group; Dr Jaspreet Singh Sidhu, vice president business development and pharmaceutical biology, Molecular Epidemiology, Inc; Dr Scott Rudge, chief operating officer, RMC Pharmaceutical Solutions; Dr Russ S Somma, president, SommaTech LLC; Dr Robert J Timko, R.P.H., director, Chemistry, Manufacturing and Controls (CMC) Group, Global Regulatory Affairs, AstraZeneca LP. Chad Wachter, senior manager, BTG and Dr Michael A. Zupon, vice president, pharmaceutical and manufacturing technology, MannKind Corporation.